Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

Most PCIs in US Now Done With Radial Access

News Daily News

Most PCIs in US Now Done With Radial Access

Michael O'Riordan

July 10, 2025

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

News Daily News

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Yael L. Maxwell

June 09, 2025

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

News Conference News EuroPCR 2025

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

May 22, 2025

Medicare Analysis Reassures on PCI in Ambulatory Surgery Centers

News Conference News SCAI 2025

Medicare Analysis Reassures on PCI in Ambulatory Surgery Centers

May 07, 2025

TAVI and Complex/High-Risk PCI Safer if Staged, Registry Confirms

News Daily News

TAVI and Complex/High-Risk PCI Safer if Staged, Registry Confirms

April 28, 2025

STEMI Revascularization Times All Over the Map: GWTG Registry

News Conference News CRT 2025

STEMI Revascularization Times All Over the Map: GWTG Registry

March 14, 2025

TCTMD’s Top 10 Most Popular Stories for February 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2025

February 28, 2025

Surgeons Formalize Support for ESC’s Stance on Revascularization in CCS

News Daily News

Surgeons Formalize Support for ESC’s Stance on CCS Revascularization

Michael O'Riordan

January 20, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.